I was appointed as a consultant at UCLH in 2007 with an interest in haemostasis and thrombosis. I am clinical lead for TTP and associated TMAs, including aHUS. I am also the clinical lead for ITP. We are a specialist centre for TTP and ITP.
Research interests include TTP, aHUS and ITP.
Since 2007 Hassan S, Westwood JP, Ellis D, Laing C, Mc Guckin S, Benjamin S, Scully M.
The utility of ADAMTS13 in differentiating TTP from other acute thrombotic
microangiopathies: results from the UK TTP Registry. Br J Haematol. 2015 Sep 11. [Epub ahead of print]
Taylor A, Neave L, Solanki S, Westwood JP, Terrinonive I, McGuckin S, Kothari J, Cooper N, Stasi R, Scully M. Mycophenolate mofetil therapy for severe immune thrombocytopenia. Br J Haematol. 2015 Aug 6. [Epub ahead of print]
Dutt T, Scully M. A proposal: the need for thrombotic thrombocytopenic purpura Specialist Centres - providing better outcomes. Br J Haematol. 2015
Scully M. Rituximab in Thrombotic Thrombocytopenic Purpura: Medical and Financial Benefits. Acta Haematol. 2015 May 20;134(3):168-169.
McCabe DJ, Murphy SJ, Starke R, Harrison P, Brown MM, Sidhu PS, Mackie IJ, Scully M, Machin SJ. Relationship between ADAMTS13 activity, von Willebrand factor antigen levels and platelet function in the early and late phases after TIA or ischaemic stroke. J Neurol Sci. 2015 Jan 15;348(1-2):35-40.
Becerra E, Scully MA, Leandro MJ, Heelas EO, Westwood JP, De La Torre I, Cambridge G. Effect of rituximab on B cell phenotype and serum B cell-activating factor levels in patients with thrombotic thrombocytopenic purpura. Clin Exp Immunol. 2015 Mar;179(3):414-25.
Scully M. Trends in the diagnosis and management of TTP: European perspective. Transfus Apher Sci. 2014 Aug;51(1):11-4. doi: 10.1016/j.transci.2014.08.001.
Paidas MJ, Forsyth C, Quéré I, Rodger M, Frieling JT, Tait RC; Recombinant Human Antithrombin Study Group. Perioperative and peripartum prevention of venous thromboembolism in patients with hereditary antithrombin deficiency using recombinant antithrombin therapy. Blood Coagul Fibrinolysis. 2014
Scully M, Thomas M, Underwood M, Watson H, Langley K, Camilleri RS, Clark A, Creagh D, Rayment R, Mcdonald V, Roy A, Evans G, McGuckin S, Ni Ainle F, Maclean R, Lester W, Nash M, Scott R, O Brien P. Congenital and acquired thrombotic thrombocytopenic purpura and pregnancy: presentation, management and outcome of subsequent pregnancies. Blood. 2014 Jul 10;124(2):211-9.
Blombery P, Scully M. Management of thrombotic thrombocytopenic purpura: current perspectives. J Blood Med. 2014 Feb 5;5:15-23.
Scully M, Goodship T. How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome. Br J Haematol. 2014 Mar;164(6):759-66.
Westwood JP, Langley K, Heelas E, Machin SJ, Scully M. Complement and cytokine response in acute Thrombotic Thrombocytopenic Purpura.. Br J Haematol. 2014 Mar;164(6):858-66.
Crawley JT, Scully MA. Thrombotic thrombocytopenic purpura: basic pathophysiology and therapeutic strategies.. Hematology Am Soc Hematol Educ Program. 2013;2013:292-9.
McGuckin S, Westwood JP, Webster H, Collier D, Leverett D, Scully M Characterization of the complications associated with plasma exchange for thrombotic thrombocytopaenic purpura and related thrombotic microangiopathic anaemias: a single institution experience.. Vox Sang. 2014 Feb;106(2):161-6
Saleh MN, Bussel JB, Cheng G, Meyer O, Bailey CK, Arning M, Brainsky A EXTEND Study Group; Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long term, open-label EXTEND study. Blood. 2013 Jan 17;121(3):537-45.
Cohen AT, Spiro TE, Büller HR, Haskell L, Hu D, Hull R, Mebazaa A, Merli G, Schellong S, Spyropoulos AC, Tapson V; MAGELLAN Investigators. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013 Feb 7;368(6):513-23.
Westwood JP, Webster H, McGuckin S, McDonald V, Machin SJ, Scully M. Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse. J Thromb Haemost. 2013 Mar;11(3):481-90
Mackie I, Langley K, Chitolie A, Liesner R, Scully M, Machin S, Peyvandi F.
Discrepancies between ADAMTS13 activity assays in patients with thrombotic microangiopathies Thromb Haemost. 2013 Jan 10;109(3).
Camilleri RS, Scully M, Thomas M, Mackie IJ, Liesner R, Chen WJ, Manns K, Machin SJ. A phenotype-genotype correlation of ADAMTS13 mutations in congenital thrombotic thrombocytopenic purpura patients treated in the United Kingdom. J Thromb Haemost. 2012 Sep;10(9):1792-801.
Scully M, Hunt BJ, Benjamin S, Liesner R, Rose P, Peyvandi F, Cheung B, Machin SJ; British Committee for Standards in Haematology. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012 Aug;158(3):323-35.
Lotta LA, Wu HM, Mackie IJ, Noris M, Veyradier A, Scully MA, Remuzzi G, Coppo P, Liesner R, Donadelli R, Loirat C, Gibbs RA, Horne A, Yang S, Garagiola I, Musallam KM, Peyvandi F. Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura. Blood. 2012 Jul 12;120(2):440-8.
Scully M. Rituximab in the treatment of TTP. Hematology. 2012 Apr;17 Suppl 1:S22-4.
Brown JH, Tellez J, Wilson V, Mackie IJ, Scully M, Tredger MM, Moore I,
McDougall NI, Strain L, Marchbank KJ, Sheerin NS, O'Grady J, Harris CL, Goodship TH. Postpartum aHUS secondary to a genetic abnormality in factor H acquired through liver transplantation. Am J Transplant. 2012 Jun;12(6):1632-6.
Cataland SR, Peyvandi F, Mannucci PM, Lämmle B, Kremer Hovinga JA, Machin SJ, Scully M, Rock G, Gilbert JC, Yang S, Wu H, Jilma B, Knoebl P. Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura. Am J Hematol. 2012 Apr;87(4):430-2.
Theodoulou A, Berryman J, Nathwani A, Scully M. Comparison of cryoprecipitate with fibrinogen concentrate for acquired hypofibrinogenaemia. Transfus Apher Sci. 2012 Apr;46(2):159-62.
Thomas MR, McDonald V, Machin SJ, Scully MA. Thrombotic thrombocytopenic
purpura associated with statin therapy. Blood Coagul Fibrinolysis. 2011
Scully M, Kaczmarski R, Myers B, Collins R, Emohare O, Bolton-Maggs PH.
Eltrombopag named patient programme for patients with chronic immune
thrombocytopenia. Br J Haematol. 2012 Apr;157(2):259-60.
Gupta RK, Ezeonyeji AN, Thomas AS, Scully MA, Ehrenstein MR, Isenberg DA. A case of pure red cell aplasia and immune thrombocytopenia complicating systemic lupus erythematosus: response to rituximab and cyclophosphamide. Lupus. 2011 Dec;20(14):1547-50.
Scully M, McDonald V, Cavenagh J, Hunt BJ, Longair I, Cohen H, Machin SJ. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood. 2011 Aug 18;118(7):1746-53.
Thomas MR, Machin SJ, Mackie I, Scully MA. B cell activating factor is
elevated in acute idiopathic thrombotic thrombocytopenic purpura. Br J Haematol. 2011 Dec;155(5):620-2.
Hart D, Sayer R, Miller R, Edwards S, Kelly A, Baglin T, Hunt B, Benjamin S, Patel R, Machin S, Scully M. Human immunodeficiency virus associated thrombotic thrombocytopenic purpura--favourable outcome with plasma exchange and prompt initiation of highly active antiretroviral therapy. Br J Haematol. 2011 May;153(4):515-9.
Cataland SR, Scully MA, Paskavitz J, Maruff P, Witkoff L, Jin M, Uva N,
Gilbert JC, Wu HM. Evidence of persistent neurologic injury following thrombotic thrombocytopenic purpura. Am J Hematol. 2011 Jan;86(1):87-9.
Lawrie AS, Green L, Canciani MT, Mackie IJ, Peyvandi F, Scully MA, Machin SJ. The effect of prion reduction in solvent/detergent-treated plasma on haemostatic variables. Vox Sang. 2010 Oct;99(3):232-8.
McDonald V, Manns K, Mackie IJ, Machin SJ, Scully MA. Rituximab
pharmacokinetics during the management of acute idiopathic thrombotic
thrombocytopenic purpura. J Thromb Haemost. 2010 Jun;8(6):1201-8.
Peyvandi F, Palla R, Lotta LA, Mackie I, Scully MA, Machin SJ. ADAMTS-13 assays in thrombotic thrombocytopenic purpura. J Thromb Haemost. 2010
McDonald V, Liesner R, Grainger J, Gattens M, Machin SJ, Scully M. Acquired, noncongenital thrombotic thrombocytopenic purpura in children and adolescents: clinical management and the use of ADAMTS 13 assays. Blood Coagul Fibrinolysis. 2010 Apr;21(3):245-50.
Scully M. Inhibitory anti-ADAMTS 13 antibodies: measurement and clinical application. Blood Rev. 2010 Jan;24(1):11-6.
Scully M, Brown J, Patel R, McDonald V, Brown CJ, Machin S. Human leukocyte antigen association in idiopathic thrombotic thrombocytopenic purpura: evidence for an immunogenetic link. J Thromb Haemost. 2010 Feb;8(2):257-62.
Scully MA, Machin SJ. Berend Houwen Memorial Lecture: ISLH Las Vegas May 2009: the pathogenesis and management of thrombotic microangiopathies. Int J Lab Hematol. 2009 Jun;31(3):268-76. Review.
Hughes C, McEwan JR, Longair I, Hughes S, Cohen H, Machin S, Scully M.
Cardiac involvement in acute thrombotic thrombocytopenic purpura: association with troponin T and IgG antibodies to ADAMTS 13. J Thromb Haemost. 2009 Apr;7(4):529-36.
McDonald V, Laffan M, Benjamin S, Bevan D, Machin S, Scully MA. Thrombotic thrombocytopenic purpura precipitated by acute pancreatitis: a report of seven cases from a regional UK TTP registry. Br J Haematol. 2009 Feb;144(3):430-3.
Scully M, Yarranton H, Liesner R, Cavenagh J, Hunt B, Benjamin S, Bevan D, Mackie I, Machin S. Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features. Br J Haematol. 2008 Sep;142(5):819-26.
Scully M, Liesner R, Burgess C, Lawrie A, Machin S. ADAMTS 13 in
non-thrombotic thrombocytopaenic purpura conditions. Br J Haematol. 2008
Apr;141(2):262-5. Epub 2008 Feb 26.
Camilleri RS, Cohen H, Mackie IJ, Scully M, Starke RD, Crawley JT, Lane DA, Machin SJ. Prevalence of the ADAMTS-13 missense mutation R1060W in late onset adult thrombotic thrombocytopenic purpura. J Thromb Haemost. 2008 Feb;6(2):331-8.
Scully M, Longair I, Flynn M, Berryman J, Machin SJ. Cryosupernatant and solvent detergent fresh-frozen plasma (Octaplas) usage at a single centre in acute thrombotic thrombocytopenic purpura. Vox Sang. 2007 Aug;93(2):154-8.
Starke R, Machin S, Scully M, Purdy G, Mackie I. The clinical utility of ADAMTS13 activity, antigen and autoantibody assays in thrombotic thrombocytopenic purpura. Br J Haematol. 2007 Feb;136(4):649-55.
Scully M, Cohen H, Cavenagh J, Benjamin S, Starke R, Killick S, Mackie I, Machin SJ. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol. 2007 Feb;136(3):451-61.